World Health Organization : Year 2006 ; World Health Organization, Immunization, Vaccines and Biologicals, No. 06.03 - in English: Proceedings of the Sixth Global Vaccine Research Forum and Parallel Satellite Symposia

By World Health Organization

Book Id: WPLBN0000194658
Format Type: PDF eBook:
File Size: 0.8 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 2006 ; World Health Organization, Immunization, Vaccines and Biologicals, No. 06.03 - in English: Proceedings of the Sixth Global Vaccine Research Forum and Parallel Satellite Symposia
Author:	World Health Organization
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Health Organization, B. W. (n.d.). World Health Organization : Year 2006 ; World Health Organization, Immunization, Vaccines and Biologicals, No. 06.03 - in English. Retrieved from https://self.gutenberg.org/

Description
Medical Reference Publication

Excerpt
Introduction Co-chairs Drs Helena Makelä and Ciro de Quadros warmly welcomed the participants and thanked them for attending this gathering of specialists in vaccine research and development. The Sixth Global Vaccine Research Forum (GVRF) is the tenth meeting in a series previously referred to as the Montreux meetings, and it is the sixth joint WHO/GAVI meeting on global vaccine research. The broad objectives of the Global Vaccine Research Forum are to: • provide an opportunity for GAVI partners to participate in shaping a global research and development agenda; • analyse the current status of vaccine research and development against AIDS, malaria and tuberculosis; • identify opportunities for vaccine research and development within WHO; • review new vaccine technologies; and • review opportunities and bottlenecks in vaccine research, development and introduction as perceived by the vaccine industry.

Table of Contents
Contents Abbreviations and acronyms .......................................................................................... v Acknowledgements ......................................................................................................... ix Introduction ..................................................................................................................... xi 1. Highlights of recent WHO activities on the research and development of new vaccines ........................................................................................................ 1 2. Development of new vaccines in the Americas: PAHO perspective ............ 4 3. The GAVI vaccine R&D projects ........................................................................ 5 3.1 Accelerating life-saving rotavirus and pneumococcal vaccines: updates on GAVI’s Accelerated Development and Introduction Plans (ADIPs) ................................................................................................. 5 3.2 Meningitis Vaccine Project update and first clinical trial .......................... 7 3.3 Pneumococcus: update on clinical trials – The Gambia ............................ 8 3.4 Pneumococcus: update on clinical trials – The Philippines ....................... 9 3.5 Update from the Enteric Vaccines Satellite Symposium ......................... 10 3.6 GAVI and the International Finance Facility for Immunization............ 12 4. Haemophilus influenzae type b (Hib) introduction and challenges: lessons learned ........................................................................................................ 15 4.1 Current status of Hib vaccine introduction .............................................. 15 4.2 Panel discussion on Hib ............................................................................... 15 5. The case for orphan vaccines: the example of leishmaniasis ........................ 20 5.1 Epidemiology of leishmaniasis .................................................................... 20 5.2 First-generation vaccines: successes and failures ..................................... 21 5.3 Second-generation vaccine trials in South America ................................ 22 5.4 Live attenuated Leishmania as vaccine candidate .................................... 22 6. Panel discussion on new regulatory approaches to vaccine licensing in developing countries ......................................................................................... 24 6.1 Introduction................................................................................................... 24 6.2 The Developing Countries’ Vaccine Regulators Network ..................... 24 6.3 WHO’s initiatives for strengthening regulatory pathways for new vaccines ................................................................................................. 26 6.4 From NRA assessment to prequalification to procurement by UNICEF and the PAHO revolving fund ............................................ 28